Table 1. Clinical Characteristics of the Study Subjects with Anaphylaxis in PFAS.
| PFAS with anaphylaxis (n=27) | PFAS with only oropharyngeal symptoms (n=130) | p value | |
|---|---|---|---|
| Sex (male) | 14 (51.9) | 69 (53.1) | 1.000 |
| Age (yr) | 27.2±18.7 | 26.2±16.7 | 0.767 |
| Allergic diseases | |||
| Bronchial asthma | 9 (33.3) | 52 (40) | 0.667 |
| Allergic rhinitis | 27 (100) | 126 (96.9) | 1.000 |
| Allergic conjunctivitis | 17 (63.0) | 75 (57.7) | 0.770 |
| Atopic dermatitis | 13 (48.1) | 34 (26.2) | 0.041 |
| Chronic urticaria | 5 (18.5) | 6 (4.6) | 0.023 |
| Drug allergy | 3 (11.1) | 11 (8.5) | 0.710 |
| Family history of allergic diseases | 21 (77.8) | 98 (75.4) | 0.986 |
| Severity of allergic rhinitis | 0.613 | ||
| Mild | 13 (48.1) | 52 (40.6) | |
| Moderate/severe | 14 (51.9) | 76 (59.4) | |
| Duration of allergic rhinitis | 0.723 | ||
| Intermittent | 13 (48.1) | 54 (42.2) | |
| Persistent | 14 (51.9) | 74 (57.8) |
PFAS, pollen-food allergy syndrome.
Data are presented as mean±standard deviation or number (%) unless otherwise indicated.